Trial Profile

A Phase II Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dostarlimab (Primary) ; Capecitabine; Fluorouracil
Indications Adenocarcinoma; Rectal cancer; Solid tumours
Focus Therapeutic Use

Most Recent Events

30 Apr 2025 Results assessing non operative management of mismatch repair deficient tumors presented at the 116th Annual Meeting of the American Association for Cancer Research
04 Jun 2024 Results (n=41) reporting efficacy data presented at the 60th Annual Meeting of the American Society of Clinical Oncology
03 Jun 2024 According to a GSK plc media release, updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com